SCHEMBL312305

SCHEMBL312305

Nc1ncccc1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29809843 1.00
SCHEMBL5328004 0.89 NOS3 (0.43)
SCHEMBL503888 0.75
SCHEMBL30258630 0.74
SCHEMBL309925 0.74
SCHEMBL29361805 0.72
SCHEMBL31092839 0.72 HDAC8 (0.45)
SCHEMBL29249875 0.72 HDAC8 (0.45)
SCHEMBL1066257 0.72 NOS3 (0.56)
SCHEMBL88338 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111892553-A Method for synthesizing ammonium acetate mediated benzothiazole compound 衡阳师范学院 2020-11-06 CN claimed
CN-109776401-A A method of preparing the chloro- 5- trifluoromethyl -2-aminopyridine of 6- 成都博腾药业有限公司 2019-05-21 CN claimed
CN-109081840-A A kind of preparation method of 5- bromo-7-azaindole 郑州大学第附属医院 2018-12-25 CN claimed
JP-6009631-A None JP disclosed
EP-4727647-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF The Broad Institute Inc. (US) 2026-04-22 EP disclosed
US-20260103465-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2026-04-16 US disclosed
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 EP disclosed
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2026-01-27 US disclosed
US-20250325548-A1 TUMOR SUPPRESSOR P73 TRANSCRIPTIONALLY REGULATES C-FLIP TO IMPEDE ITS PRIMING OF EXTRINSIC APOPTOSIS WHILE AN EXAMPLE SWITCHER COMPOUND CB-7587351 DEGRADES C-FLIP PROTEIN UNIV BROWN (US) 2025-10-23 US disclosed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 EP disclosed
WO-1999020624-A1 BICYCLIC KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 1999-04-29 WO disclosed
WO-1998022457-A9 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS 1998-08-20 WO disclosed
WO-1998022457-A1 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS AMGEN INC. (US) 1998-05-28 WO disclosed
JP-H069631-A NEW PRODUCTION OF PYRAZOLOPYRIDINE FUJISAWA PHARMACEUT CO LTD 1994-01-18 JP disclosed
EP-0120589-B1 IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP disclosed
US-4621084-A CARDIOTONIC, ANTIULCER FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-11-04 US disclosed
EP-0120589-A1 Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-03 EP disclosed
US-4146642-A ANTHELMINTICS MERCK & CO., INC. (US) 1979-03-27 US disclosed
US-4105767-A ANTHELMINTICS MERCK & CO., INC. (US) 1978-08-08 US disclosed